"But, that doesn't mean I'm not acknowledging UCLA's theory that DCVax-L potentially changes the patients DNA to make them more susceptible to TMZ. Perhaps patients in the past who were not responsive to TMZ suddenly become responsive to TMZ. Data has been shared on this iHub regarding that phenomenon. I can smile and agree with you that TMZ is a low-hanging fruit. I truly believe there is a synergy with TMZ+Vaccine" RK
I have to assume that you are stating that the DCVAX-L is potentially changing the GBM patient's tumor DNA profile and not that DCVAX-L is mutagenic. I don't recall UCLA ever stating that their vaccine can change the MGMT status of the patients. TMZ if I remember correctly is dependent on MGMT status for its MOA. TMZ usage is counter-intuitive but research seems to support its potential to change the tumor microenvironment by reducing the level of immuno-suppressive elements (along with the rest of the immune system which is not good because it leads to lymphopenia).
That study compared apples to hybrid apple/pears. The age groups were different and individual patient characteristics not revealed. How many besides the 2 month survivor didn't survive for even the 6 months of standard Stupp? The one outlier from a total patient group this size fell into the extended TMZ group. Good trend but this is why FDA requires blinded clinical trials for proof. Does this argument sound familiar? Glad you are smiling.
News 
Market Data 
Discover 
